COVID19 Update: For your safety, you will be asked to use a mask, if you do not have one, a mask will be provided. If a person presents with a temperature, you will be asked to return home and further instructions will be given by your health care team. For our patient’s protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. Telemedicine visits are available for routine office visits. All Patients – Very Important: Regardless of vaccination status.  If you are experiencing a fever or cold-like like symptoms, which also include GI Symptoms and Diarrhea, you should contact your Virginia Cancer Specialists Advice Line before visiting our clinics for scheduled appointments. This includes symptoms of respiratory illness, such as coughing or difficulty breathing.  More Information-PLEASE CLICK HERE

Journal of Clinical Oncology - ASCO Pub - Abstract - Pancreatic Cancer and other GI Tumors harboring a KRAS (G12C) Mutation. Alex Spria, MD, PhD, FACP

Virginia Cancer Specialists Practice Blog

January 20, 2022
Virginia Cancer Specialists » VCS Practice News » Physicians » VCS Practice News » Alex Spira MD PhD FACP » Journal of Clinical Oncology – ASCO Pub – Abstract – Pancreatic Cancer and other GI Tumors harboring a KRAS (G12C) Mutation. Alex Spria, MD, PhD, FACP

KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation.

, , , , , , , , , , , , , Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ; US Oncology Research/Virginia Cancer Specialists, Fairfax, VA; Memorial Sloan Kettering Cancer Center, New York, NY; Southern California Permenente Medical Group, Los Angeles, CA; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Sarah Cannon Research Institute, Nashville, TN; Texas Oncology, Dallas, TX; Yale University School of Medicine, New Haven, CT; Mirati Therapeutics, Inc., San Diego, CA; Janssen Research and Development, LLC, San Diego, CA; Henry Ford Cancer Institute, Henry Ford Health System, Detroit, MI

 

Learn More here: https://ascopubs.org/doi/10.1200/JCO.2022.40.4_suppl.519?utm_medium=cpc&utm_campaign=J_Clin_Oncol_TrendMD_0&utm_source=TrendMD#.Yei3b8vXpqs.twitter